The results suggest AR-V7-postive patients should be treated with chemotherapy over AR-directed hormonal therapies to which they are highly resistant.
The company is offering about 3.6 million shares of its common stock, and warrants to purchase 715,000 shares of its stock.
Bio-Rad reported $598.2 million in revenues for the quarter, down from $602.6 million a year ago but surpassing the average analysts' estimate of $593.4 million.
The firm has also created a qPCR-based Staphylococcus aureus resistance gene assay with a run time of three minutes.
Available in March, the PCR-based FilmArray 2.0 platform has higher throughput and takes up a smaller footprint.
In Science this week: gene linked to expansion of the human neocortex, and more.
The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.
Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.
Joel Achenbach explores at National Geographic why people find science difficult to believe.